PULMATRIX, INC.

Profile

Company Names

PULMATRIX, INC.
RUTHIGEN, INC.

Addresses

945 CONCORD STREET, SUITE 1217, FRAMINGHAM, MA 01701

99 HAYDEN AVENUE, SUITE 390, LEXINGTON, MA 02421

99 HAYDEN AVENUE, SUITE 390, LEXINGTON, MA 02421

2455 BENNETT VALLEY RD. SUITE C116, SANTA ROSA, CA 95404

Phone Numbers

(888) 355-4440
781-357-2333
(781) 357-2333
(707) 525-9900

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, PHARMACEUTICALS

Year Incorporated:

2013

State Incorporated:

DELAWARE

Total Amount Raised:

$18,652,665.00

Number of Funding Rounds:

10
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
10
2026-03-26 
$1,000,000.00 
$1,000,000.00 
$0.00 
Equity 
9
2021-02-16 
$0.00 
$3,250,000.00 
$3,250,000.00 
 
8
2020-07-09 
$45,000.00 
$19,629,373.00 
$19,584,373.00 
 
7
2020-04-16 
$8,070,723.00 
$8,070,723.00 
$0.00 
 
6
2019-02-12 
$2,489,820.00 
$2,489,820.00 
$0.00 
 
5
2019-02-04 
$73,531.00 
$73,531.00 
$0.00 
 
4
2019-01-31 
$21,565.00 
$21,565.00 
$0.00 
 
3
2018-12-03 
$3,656,250.00 
$3,656,250.00 
$0.00 
 
2
2015-06-15 
$687,500.00 
$687,500.00 
$0.00 
Equity 
1
2015-06-01 
$2,608,276.00 
$2,608,526.00 
$250.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
AKIHISA 
 
AKAO 
DIRECTOR
HOJABR 
 
ALIMI 
EXECUTIVE OFFICER, PROMOTER
RICHARD 
 
BATYCKY 
DIRECTOR
TODD 
 
BAZEMORE 
DIRECTOR
CHRISTOPHER 
 
CABELL 
DIRECTOR
RICHARD 
 
CONLEY 
DIRECTOR, PROMOTER
WILLIAM 
 
DUKE 
EXECUTIVE OFFICER
GREGORY 
 
FRENCH 
DIRECTOR, PROMOTER
SAMEER 
 
HARISH 
EXECUTIVE OFFICER, PROMOTER
DAVID 
 
HAVA 
EXECUTIVE OFFICER
MICHAEL 
J. 
HIGGINS 
DIRECTOR
PETER 
 
LUDLUM 
EXECUTIVE OFFICER
AMIT 
D. 
MUNSHI 
DIRECTOR
 
OCULUS INNOVATIVE SCIENCES, INC. 
PROMOTER
TEOFILO 
 
RAAD 
EXECUTIVE OFFICER, DIRECTOR
JAMES 
 
ROACH 
EXECUTIVE OFFICER
MATTHEW 
 
SHERMAN 
DIRECTOR
MICHELLE 
S. 
SIEGERT 
EXECUTIVE OFFICER, DIRECTOR
ANAND 
 
VARADAN 
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2026-03-26 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2020-07-09 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2021-02-16 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2020-07-09 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2020-04-16 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2019-01-31 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2019-02-04 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2019-02-12 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2018-12-03 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2015-06-15 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2015-06-15 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2015-06-15 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2015-06-15 
D
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2015-06-01 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
NONE
NONE
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
DAWSON JAMES SECURITIES INC.